Chile Menopause Drugs Market
市场规模（十亿美元）
CAGR :
% 
 Forecast Period |
2022 –2029 |
 Market Size (Base Year) |
USD 12.35 Million |
 Market Size (Forecast Year) |
USD 16.62 Million |
 CAGR |
% |
| Major Markets Players |
>智利更年期药物市场，按阶段（绝经后、围绝经期和绝经期）、类型（非激素疗法和激素疗法）、更年期症状（血管舒缩症状、萎缩性阴道炎、性交困难、骨质疏松症、关节痛、抑郁、体重增加等）、剂型（片剂、乳膏、贴剂/薄膜、环、凝胶、注射剂、喷雾剂等）、给药途径（口服、肠胃外、透皮、阴道等）、最终用户（医院、诊所家庭医疗保健等）、分销渠道（医院药房、零售药房和网上药房）划分，行业趋势及预测至 2029 年。
市场分析与洞察：智利更年期药物市场
预计智利更年期药物市场将在 2022 年至 2029 年的预测期内实现市场增长。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，该市场将以 3.9% 的复合年增长率增长，预计将从 2021 年的 1235 万美元增至 2029 年的 1662 万美元。智利女性老龄化人口的增加以及用于治疗更年期的激素和非激素治疗药物的持续研发可能是推动预测期内市场增长的主要驱动力。
更年期是女性月经周期结束的时间。女性在停经 12 个月后即可诊断出更年期。更年期可能发生在 40 多岁或 50 多岁。在更年期期间，女性体内的雌激素和孕激素分泌减少。激素水平降低会导致更年期症状的出现，例如潮热、情绪变化、性欲改变、失眠、皮肤干燥和体重增加。
女性选择用激素和非激素疗法来治疗更年期症状。激素疗法药物是雌激素/孕酮/孕激素激素疗法的联合疗法，雌激素、孕酮、雌激素与孕酮药物的混合物以及醋酸甲羟孕酮用于提高激素水平以缓解一些更年期症状。仅含孕激素的药物与仅含雌激素的药物一起服用，以降低仍有子宫的女性患子宫内膜癌的几率。
根据人口参考局的数据，智利拥有拉丁美洲 11.8% 的老年人口（65 岁以上）。智利人口老龄化是由于生育率和死亡率上升造成的。这种转变导致对老年人长期护理的需求增加，特别是那些需要帮助进行日常生活活动的人。智利 49 岁的女性已开始进入更年期。2017 年，国家统计研究所的数据显示，在智利，老年人占总人口的 16.2%，30 年后，四分之一的人将超过 60 岁。
激素疗法 (HT) 是政府为治疗更年期症状而采取的举措之一。政府提高人们对更年期症状治疗的认识或采取举措，以改善更年期症状治疗的健康、降低治疗成本和提高治疗安全性。
例如，
- 智利卫生部出台了老年人预防医学检查（EMPAM），促进老年人口的健康老龄化，确定每个老年人根据丧失功能的风险进行分类，并采取行动，明确预防、治疗或康复，确保良好的生活质量。
智利更年期药物市场增长的驱动因素包括研发力度加大、女性老龄化人口增加、智利政府组织和资金增加、报销和产品审批增加。然而，预计会制约市场的因素包括更年期药物成本上涨、产品召回增加。智利民众对更年期知识缺乏认识以及更年期的复杂性。
- 另一方面，市场参与者的战略举措、医疗保健支出的增加以及膳食补充剂的使用可能为智利更年期药物市场的增长提供机会。对熟练专业知识和监管部门批准的需求可能会给智利更年期药物市场带来挑战。智利更年期药物市场最近出现了一些发展。
智利更年期药物市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品审批、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情况，请联系我们获取分析师简报，我们的团队将帮助您创建收入影响解决方案，以实现您的预期目标。
智利更年期药物市场范围和市场规模
智利更年期药物市场分为七个部分：阶段、类型、更年期症状、剂型、给药途径、最终用户和分销渠道。
- 根据阶段，智利更年期药物市场分为绝经后、围绝经期和绝经期。2022 年，绝经后阶段预计将占据智利更年期药物市场的主导地位，因为所选药物具有很高的治疗潜力。
- 根据类型，智利更年期药物市场分为非激素疗法和激素疗法。2022 年，非激素疗法领域预计将主导智利更年期药物市场，因为可以确保药物目标具有潜在的治疗益处、补充剂的易用性以及提高女性对更年期后问题的认识。
- 根据更年期症状，智利更年期药物市场分为血管舒缩症状、萎缩性阴道炎、性交困难、骨质疏松症、关节痛、抑郁症、体重增加等。2022 年，由于治疗因血管舒缩症状引起的潮热和阴道干燥的需求增加、市场参与者对研发 (R&D) 的投资以及可支配收入的增加，预计血管舒缩药物将主导智利更年期药物市场。
- 根据剂型，智利更年期药物市场分为片剂、乳膏、贴剂/薄膜、环、凝胶、注射剂、喷雾剂等。2022 年，片剂市场预计将在智利更年期药物市场占据主导地位，这是由于智利中年女性越来越倾向于通过口服药物治疗潮热和性交困难，对更年期症状发作的意识增强，以及片剂零售量增长。
- 根据给药途径，智利更年期药物市场分为口服、肠外、透皮、阴道和其他。 2022 年，口服药物市场预计将占据智利更年期药物市场的主导地位，因为公司提供的大多数药物和消费者使用率较高的药物都是口服药物，因此预计该市场将占据主导地位。
- 根据最终用户，智利更年期药物市场分为医院、诊所、家庭医疗保健和其他。到 2022 年，医院部门预计将主导智利更年期药物市场，因为外泌体研发的增加以及智利政府对更年期药物开发的资助，而妇科医生提供的关于正确使用激素和非激素疗法的正确处方和指导预计将主导市场。
- 根据分销渠道，智利更年期药物市场分为医院药房、零售药房和网上药房。预计到 2022 年，医院药房将主导智利更年期药物市场，因为与认证处方人员和卫生专业人员在使用抗抑郁药物方面的互动增加，并且保证付款，预计将主导市场。
智利更年期药物市场国家级分析
智利更年期药物市场分为七个部分：阶段、类型、更年期症状、剂型、给药途径、最终用户和分销渠道。
- 2022 年，由于制药公司对更年期药物的研发力度加大，智利将占据市场主导地位。
报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。新销售、替代销售、国家人口统计、监管法案和进出口关税等数据点是用于预测单个国家市场情景的一些主要指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀少的竞争而面临的挑战、销售渠道的影响。
智利更年期药物在新兴经济体的增长潜力和市场参与者的战略举措正在为智利更年期药物市场创造新的机遇
智利更年期药物市场还为您提供每个国家特定行业增长的详细市场分析，包括伤口清创设备销售、智利更年期药物发展的影响以及监管环境的变化及其对智利更年期药物市场的支持。数据涵盖 2012 年至 2020 年的历史时期。
竞争格局和智利更年期药物市场份额分析
智利更年期药物市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对智利更年期药物市场的关注有关。
智利主要提供更年期药物的公司有雅培公司、葛兰素史克公司、诺华公司、诺和诺德公司、辉瑞公司、梯瓦制药工业有限公司、拜耳公司、艾伯维公司、SAVAL Pharmaceuticals、Tecnofarma SA、SYNTHON、Laboratorios Maver、Knop Laboratories、Fresenius Kabi Chile、Megalabs Chile SA 和 ITF-LABOMED FARMACEUTICA LTDA 等。
市场参与者的战略举措以及智利更年期药物激素和非激素治疗的研究和开发预计将增加更年期药物的净收入和销售额。
例如，
- 辉瑞公司的 Caltrate 用于治疗由低钙水平引起的病症，如骨质流失（骨质疏松症）、骨质脆弱（骨质软化症或佝偻病）、甲状旁腺功能减退（甲状旁腺功能减退症）和某种肌肉疾病（潜伏性手足搐溺症）
市场参与者的合作、合资和其他策略正在增强公司在智利更年期药物市场的市场，这也为组织改善其治疗产品供应提供了好处。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF CHILE MENOPAUSE DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 CHILE MENOPAUSE DRUGS MARKET: SEGMENTATION
2.1 MARKETS COVERED
2.2 COUNTRY SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 CAUSE SEGMENT LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDEMIOLOGY
4.2 PESTEL'S MODEL
4.3 PORTER'S FIVE FORCES MODEL
5 PIPELINE ANALYSIS FOR CHILE MENOPAUSE DRUGS MARKET
6 CHILE MENOPAUSE DRUGS MARKET, COUNTRY SUMMARY
6.1 OVERVIEW
7 CHILE MENOPAUSE DRUG TREATMENT MARKET: REGULATORY SCENARIO
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 LOW AGE OF MENOPAUSE DISORDER OCCURRENCE AS COMPARED TO OTHER REGIONS
8.1.2 RISE IN AGEING POPULATION AMONG WOMEN IN CHILE
8.1.3 RISE IN RESEARCH AND DEVELOPMENT
8.1.4 RISE IN PHYSICAL INACTIVITY AND SEDENTARY LIFESTYLE
8.1.5 REIMBURSEMENT FOR MENOPAUSE TREATMENT
8.2 RESTRAINTS
8.2.1 RISE IN COST OF THE MENOPAUSE DRUGS
8.2.2 PATENT EXPIRY
8.2.3 COMPLEXITY IN MENOPAUSE
8.2.4 LACK OF AWARENESS ABOUT MENOPAUSE
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVE BY MARKET PLAYERS
8.3.2 RISE IN HEALTHCARE EXPENDITURE
1.3.2 PRESENCE OF A STRONG PRODUCT PIPELINE
8.4 CHALLENGES
8.4.1 ADVERSE EFFECTS OF MEDICATION
8.4.2 AVAILABILITY OF ALTERNATIVES
9 IMPACT OF COVID-19 ON CHILE MENOPAUSE DRUG TREATMENT MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT ON SUPPLY CHAIN
9.3 IMPACT ON DEMAND
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS
9.5 CONCLUSION
10 CHILE MENOPAUSE DRUGS MARKET, BY STAGES
10.1 OVERVIEW
10.2 POSTMENOPAUSE
10.3 PERIMENOPAUSE
10.4 MENOPAUSE
11 CHILE MENOPAUSE DRUGS MARKET, BY TYPE
11.1 OVERVIEW
11.2 NON-HORMONAL THERAPY
11.2.1 MEDICATION
11.2.1.1 ANTI-DEPRESSANTS
11.2.1.2 PAROXETINE
11.2.1.3 GABAPENTIN
11.2.1.4 CLONIDINE
11.2.1.5 OSPEMIFENE
11.2.1.6 OTHERS
11.2.2 SUPPLEMENTS
11.2.2.1 HERBAL SUPPLEMENTS
11.2.2.1.1 GINSENG
11.2.2.1.2 ASHWAGANDHA
11.2.2.1.3 OTHERS
11.2.2.2 VITAMIN D
11.2.2.3 OTHERS
11.3 HORMONAL THERAPY
11.3.1 ESTROGEN
11.3.1.1 17 B- ESTRADIOL
11.3.1.2 CONJUGATED ESTROGEN
11.3.1.3 ESTRADIOL HEMIHYDRATE
11.3.1.4 ESTERIFIED ESTROGEN
11.3.1.5 ESTERIFIED ACETATE
11.3.1.6 ESTROPIPATE
11.3.1.7 OTHERS
11.3.2 COMBINES ESTROGEN & PROGESTOGEN DRUGS
11.3.2.1 17 B- ESTRADIOL (E) + NORETHINODRONE ACETATE (P)
11.3.2.2 CONJUGATED ESTROGENS (E) + MEDROXYPROGESTERONE ACETATE (P)
11.3.2.3 ETHINYL ESTRADIOL (E) + NORETHINDRONE ACETATE (P)
11.3.2.4 OTHERS
11.3.3 MEDROXYPROGESTERONE ACETATE
12 CHILE MENOPAUSE DRUGS MARKET, BY MENOPAUSE SYMPTOMS
12.1 OVERVIEW
12.2 VASOMOTOR SYMPTOMS
12.2.1 HORMONAL THERAPY
12.2.2 NON-HORMONAL THERAPY
12.3 ATROPHIC VAGINITIS
12.3.1 HORMONAL THERAPY
12.3.2 NON-HORMONAL THERAPY
12.4 DYSPAREUNIA
12.4.1 HORMONAL THERAPY
12.4.2 NON-HORMONAL THERAPY
12.5 OSTEOPOROSIS
12.5.1 NON-HORMONAL THERAPY
12.5.2 HORMONAL THERAPY
12.6 DEPRESSION
12.6.1 NON-HORMONAL THERAPY
12.6.2 HORMONAL THERAPY
12.7 JOINT PAIN
12.7.1 NON-HORMONAL THERAPY
12.7.2 HORMONAL THERAPY
12.8 WEIGHT GAIN
12.8.1 HORMONAL THERAPY
12.8.2 NON- HORMONAL THERAPY
12.9 OTHERS
13 CHILE MENOPAUSE DRUGS MARKET, BY DOSAGE FORM
13.1 OVERVIEW
13.2 TABLET
13.3 CREAM
13.4 PATCH/FILM
13.5 RINGS
13.6 GEL
13.7 INJECTION SHOT
13.8 SPRAY
13.9 OTHERS
14 CHILE MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.3 PARENTERAL
14.3.1 INTRAVENOUS
14.3.2 SUBCUTANEOUS
14.3.3 OTHERS
14.4 TRANSDERMAL
14.5 VAGINAL
14.6 OTHERS
15 CHILE MENOPAUSE DRUGS MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 CLINICS
15.4 HOME HEALTHCARE
15.5 OTHERS
16 CHILE MENOPAUSE DRUGS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 RETAIL PHARMACY
16.3 HOSPITAL PHARMACY
16.4 ONLINE PHARMACY
17 CHILE MENOPAUSE DRUGS MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: CHILE
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 BAYER AG
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 PRODUCT PORTFOLIO
19.1.4 RECENT DEVELOPMENTS
19.2 PFIZER INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 PRODUCT PORTFOLIO
19.2.4 RECENT DEVELOPMENTS
19.3 NOVARTIS AG
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 PRODUCT PORTFOLIO
19.3.4 RECENT DEVELOPMENT
19.4 TEVA PHARMACEUTICAL INDUSTRIES LTD
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 PRODUCT PORTFOLIO
19.4.4 RECENT DEVELOPMENTS
19.5 KNOP LABORATORIES
19.5.1 COMPANY SNAPSHOT
19.5.2 PRODUCT PORTFOLIO
19.5.3 RECENT DEVELOPMENTS
19.6 SAVAL PHARMACEUTICALS
19.6.1 COMPANY SNAPSHOT
19.6.2 PRODUCT PORTFOLIO
19.6.3 RECENT DEVELOPMENT
19.7 ITF-LABOMED FARMACEUTICA LTDA.
19.7.1 COMPANY SNAPSHOT
19.7.2 PRODUCT PORTFOLIO
19.7.3 RECENT DEVELOPMENTS
19.8 TECNOFARMA S.A.
19.8.1 COMPANY SNAPSHOT
19.8.2 PRODUCT PORTFOLIO
19.8.3 RECENT DEVELOPMENT
19.9 MEGALABS CHILE S.A
19.9.1 COMPANY SNAPSHOT
19.9.2 PRODUCT PORTFOLIO
19.9.3 RECENT DEVELOPMENTS
19.1 ABBVIE INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 REVENUE ANALYSIS
19.10.3 PRODUCT PORTFOLIO
19.10.4 RECENT DEVELOPMENTS
19.11 ABBOTT (2021)
19.11.1 COMPANY SNAPSHOT
19.11.2 REVENUE ANALYSIS
19.11.3 PRODUCT PORTFOLIO
19.11.4 RECENT DEVELOPMENT
19.12 FRESENIUS KABI CHILE
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENT
19.13 GLAXO SMITH KLINE PLC(2021)
19.13.1 COMPANY SNAPSHOT
19.13.2 REVENUE ANALYSIS
19.13.3 PRODUCT PORTFOLIO
19.14 LABORATORIOS MAVER
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENTS
19.15 NOVO NORDISK A/S
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 SYNTHON
19.16.1 COMPANY SNAPSHOT
19.16.2 PRODUCT PORTFOLIO
19.16.3 RECENT DEVELOPMENT
20 QUESTIONNAIRE
21 RELATED REPORTS
表格列表
TABLE 1 MEDICINES SUBJECTED TO PATENT EXPIRY
TABLE 2 CHILE MENOPAUSE DRUGS MARKET, BY STAGES, 2020-2029 (USD MILLION)
TABLE 3 CHILE MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 4 CHILE NON–HORMONAL THERAPY IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 5 CHILE MEDICATION IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 6 CHILE SUPPLEMENTS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 7 CHILE HERBAL SUPPLEMENTS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 8 CHILE HORMONAL THERAPY IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 9 CHILE ESTROGEN IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 10 CHILE COMBINED ESTROGEN & PROGESTOGEN DRUGS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 11 CHILE MENOPAUSE DRUGS MARKET, BY MENOPAUSE SYMPTOMS, 2020-2029 (USD MILLION)
TABLE 12 CHILE VASOMOTOR SYMPTOMS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 13 HORMONAL THERAPY FOR THE MANAGEMENT OF VULVOVAGINAL ATROPHY
TABLE 14 CHILE ATROPHIC VAGINITIS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 15 CHILE DYSPAREUNIA IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 16 CHILE OSTEOPOROSIS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 17 CHILE DEPRESSION IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 18 CHILE JOINT PAIN IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 19 CHILE VASOMOTOR SYMPTOMS IN MENOPAUSE DRUGS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 20 CHILE MENOPAUSE DRUGS MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)
TABLE 21 CHILE MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 22 CHILE PARENTERAL IN MENOPAUSE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 23 CHILE MENOPAUSE DRUGS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 24 CHILE MENOPAUSE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 CHILE MENOPAUSE DRUGS MARKET: SEGMENTATION
FIGURE 2 CHILE MENOPAUSE DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 CHILE MENOPAUSE DRUGS MARKET: DROC ANALYSIS
FIGURE 4 CHILE MENOPAUSE DRUGS MARKET: REGIONAL VS COUNTRY ANALYSIS
FIGURE 5 CHILE MENOPAUSE DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 CHILE MENOPAUSE DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 CHILE MENOPAUSE DRUGS MARKET: DBMR POSITION GRID
FIGURE 8 CHILE MENOPAUSE DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 CHILE MENOPAUSE DRUGS MARKET: END USER COVERAGE GRID
FIGURE 10 CHILE MENOPAUSE DRUGS MARKET: SEGMENTATION
FIGURE 11 RISE IN AGEING POPULATION AMONG WOMEN IN CHILE IS EXPECTED TO DRIVE CHILE MENOPAUSE DRUGS MARKET FROM 2022 TO 2029
FIGURE 12 POSTMENOPAUSE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE CHILE MENOPAUSE DRUGS MARKET FROM 2022 & 2029
FIGURE 13 REGULATORY PROCESS OF DRUGS AND BIOLOGICS APPROVAL IN CHILE
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF CHILE MENOPAUSE DRUGS MARKET
FIGURE 15 CHILE IMPORTS: MEDICINAL AND PHARMACEUTICAL PRODUCT
FIGURE 16 CHILE MENOPAUSE DRUGS MARKET: BY STAGES, 2021
FIGURE 17 CHILE MENOPAUSE DRUGS MARKET: BY STAGES, 2020-2029 (USD MILLION)
FIGURE 18 CHILE MENOPAUSE DRUGS MARKET: BY STAGES, CAGR (2022-2029)
FIGURE 19 CHILE MENOPAUSE DRUGS MARKET: BY STAGES, LIFELINE CURVE
FIGURE 20 CHILE MENOPAUSE DRUGS MARKET: BY TYPE, 2021
FIGURE 21 CHILE MENOPAUSE DRUGS MARKET: BY TYPE, 2020-2029 (USD MILLION)
FIGURE 22 CHILE MENOPAUSE DRUGS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 23 CHILE MENOPAUSE DRUGS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 24 CHILE MENOPAUSE DRUGS MARKET: BY MENOPAUSE SYMPTOMS, 2021
FIGURE 25 CHILE MENOPAUSE DRUGS MARKET: BY MENOPAUSE SYMPTOMS, 2020-2029 (USD MILLION)
FIGURE 26 CHILE MENOPAUSE DRUGS MARKET: BY MENOPAUSE SYMPTOMS, CAGR (2022-2029)
FIGURE 27 CHILE MENOPAUSE DRUGS MARKET: BY MENOPAUSE SYMPTOMS, LIFELINE CURVE
FIGURE 28 CHILE MENOPAUSE DRUGS MARKET: BY DOSAGE FORM, 2021
FIGURE 29 CHILE MENOPAUSE DRUGS MARKET: BY DOSAGE FORM, 2020-2029 (USD MILLION)
FIGURE 30 CHILE MENOPAUSE DRUGS MARKET: BY DOSAGE FORM, CAGR (2022-2029)
FIGURE 31 CHILE MENOPAUSE DRUGS MARKET: BY DOSAGE FORM, LIFELINE CURVE
FIGURE 32 CHILE MENOPAUSE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021
FIGURE 33 CHILE MENOPAUSE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
FIGURE 34 CHILE MENOPAUSE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)
FIGURE 35 CHILE MENOPAUSE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 CHILE MENOPAUSE DRUGS MARKET: BY END USER, 2021
FIGURE 37 CHILE MENOPAUSE DRUGS MARKET: BY END USER, 2020-2029 (USD MILLION)
FIGURE 38 CHILE MENOPAUSE DRUGS MARKET: BY END USER, CAGR (2022-2029)
FIGURE 39 CHILE MENOPAUSE DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 CHILE MENOPAUSE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 41 CHILE MENOPAUSE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
FIGURE 42 CHILE MENOPAUSE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 43 CHILE MENOPAUSE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 CHILE MENOPAUSE DRUGS MARKET: COMPANY SHARE 2021 (%)
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
